Evoked potentials are of little use in the diagnosis or monitoring of MS: No

Fernández, Óscar; Fernández, Victoria

doi:10.1177/1352458513506955

Cited by 6 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four years ago, the role of evoked potentials (EP) for diagnosis and monitoring of multiple sclerosis (MS) was discussed in this journal. 1 , 2 The bottom line of the commentary by Hutchinson 3 was that despite some strong arguments for the use of EP in predicting and monitoring the disease course, emerging magnetic resonance imaging (MRI) techniques would finally become the methods of choice for these purposes. While advances in imaging and the understanding of its biological substrate have made considerable progress and provide a unique avenue for the characterization of tissue damage and repair, 4 , 5 many of the proposed techniques remain to be validated and are available at specialized centers only.…”

Section: Introductionmentioning

confidence: 99%

A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS

2017

View full text Add to dashboard Cite

Evoked potentials (EP) characterize signal conduction in selected tracts of the central nervous system in a quantifiable way. Since alteration of signal conduction is the main mechanism of symptoms and signs in multiple sclerosis (MS), multimodal EP may serve as a representative measure of the functional impairment in MS. Moreover, EP have been shown to be predictive for disease course, and thus might help to select patient groups at high risk of progression for clinical trials. EP can detect deterioration, as well as improvement of impulse propagation, independently from the mechanism causing the change. Therefore, they are candidates for biomarkers with application in clinical phase-II trials. Applicability of EP in multicenter trials has been limited by different standards of registration and assessment.

show abstract

Section: Introductionmentioning

confidence: 99%

A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS

2017

View full text Add to dashboard Cite

show abstract

“…EPs are convenient tools that could sensitively detect subclinical abnormalities that are not captured by neuroimaging studies [17] . Therefore EPs could provide valuable information about disease activity and are widely applied in daily clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Clinical Correlations of Motor and Somatosensory Evoked Potentials in Neuromyelitis Optica

Tsao

Lyu

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundMotor and somatosensory evoked potentials (MEPs and SSEPs) are sensitive tools for detecting subclinical lesions, assessing disease severity, and determining the prognosis for outcomes of patients with inflammatory neurological diseases such as multiple sclerosis. However, their roles in neuromyelitis optica (NMO), a severe inflammatory neurological disease that predominantly involves optic nerves and spinal cord, have not yet been clarified.Methods and FindingsClinical symptoms and examination findings at relapses of 30 NMO patients were retrospectively reviewed. Abnormal MEPs were observed in 69.2% of patients. Patients with abnormal motor central conduction time (CCT) of the lower limbs had higher Kurtzke Expanded Disability Status Scale (EDSS) scores than those with normal responses (P = 0.027). Abnormal SSEPs were found in 69.0% of patients. Patients with abnormal lower limb sensory CCT had higher EDSS scores than those with normal responses (P = 0.019). In 28 patients followed up more than 6 months, only one of 11 patients (9.1%) with normal SSEPs of the lower limbs had new relapses within 6 months, whereas 8 of 17 patients (47.1%, P = 0.049) with abnormal SSEPs of the lower limbs had new relapses.ConclusionsThese results indicate MEPs and SSEPs of the lower limbs are good indicators for the disability status at relapses of NMO. Lower limb SSEPs may be a good tool for reflecting the frequency of relapses of NMO.

show abstract

“…In the last decade, the relation between evoked potentials (EPs) and EDSS was studied by many authors including our group and most results showed the presence of significant correlations depending on the characteristics of the study samples and type of EPs involved [9][10][11][12][13][14][15][16]. According to our experience, we suggest that the EP-score should also be considered as an independent outcome measure since it mostly represents subclinical rather than clinical disability and could therefore improve the assessment of treatment effects.…”

Section: Introductionmentioning

confidence: 80%

“…The authors, however, acknowledged that treatment with IFNβ might positively affect other outcome measures not considered in their analyses. In fact, in spite of its wellrecognized limitations, the Expanded Disability Status Scale (EDSS) is still the only internationally recognized tool for measuring multiple sclerosis (MS) disability in both pharmacological and clinical trials [3,8,9].…”

Section: Introductionmentioning

confidence: 99%